|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
90,000,000 |
Market
Cap: |
18.00(M) |
Last
Volume: |
6,835 |
Avg
Vol: |
0 |
52
Week Range: |
$0.2 - $0.7027 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile iBio is a developer of biopharmaceuticals and FastPharming Manufacturing System (the FastPharming System) ®. Co. applies its technologies to develop product candidates to fight fibrotic diseases, cancers, and infectious diseases. Co. uses its FastPharming Manufacturing System and Glycaneering Services to build biologic drug candidates. Co.'s segments are: Biopharmaceuticals, which includes development and licensing in therapeutics and vaccines; and Bioprocessing, which includes services (FastPharming, process development, manufacturing, as well as bioanalytical and other services) and products (growth factors, lectins, and monoclonal antibodies) for research and further manufacturing uses.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|